DelveInsight’s, “Chronic Hepatitis Delta Virus Infection Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the Chronic Hepatitis Delta Virus Infection pipeline drug profiles, including Chronic Hepatitis Delta Virus Infection clinical trials and nonclinical stage products. It also covers the Chronic Hepatitis Delta Virus Infection therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Hepatitis Delta Virus Infection Pipeline Report

 

• DelveInsight’s Chronic Hepatitis Delta Virus Infection Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Chronic Hepatitis Delta Virus Infection treatment.

 

• The leading Chronic Hepatitis Delta Virus Infection Companies include Janssen Pharmaceuticals, Eiger Biopharmaceutical, Pharma Essentia, Vir Biotechnology, Inc., Eiger BioPharmaceutical, Hoffmann-La Roche, Merck Sharp & Dohme LLC, and others

 

• Promising Chronic Hepatitis Delta Virus Infection Pipeline Therapies include Pegylated Interferon (PEG-IFN) alfa-2a, tenofovir, and others

 

• The Chronic Hepatitis Delta Virus Infection companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis Delta Virus (HDV) Infection R&D. The Chronic Hepatitis Delta Virus Infection therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis Delta Virus (HDV) Infection.

 

Request a sample and discover the recent breakthroughs happening in the Chronic Hepatitis Delta Virus Infection Pipeline landscape @ Chronic Hepatitis Delta Virus Infection Pipeline Outlook

 

Chronic Hepatitis Delta Virus Infection Overview

Chronic Hepatitis Delta Virus (HDV) Infection is caused by hepatitis D virus with simultaneous presence of hepatitis B infection. HDV-HBV co-infection is the most severe form of chronic infection leading liver-related death and hepatocellular carcinomas. The virus can transmit from person to person and affect nearly 5% of population with prior HBV infection.

 

Chronic Hepatitis Delta Virus Infection Emerging Drugs Profile

 

• Lonafarnib: Eiger Biopharmaceuticals

Eiger’s lead drug candidate, Lonafarnib is an orally administered small molecule in development for the treatment of chronic HDV infection. The Phase I and II clinical trials have demonstrated good safety and efficacy. The drug acts by blocking the key enzyme required by HDV virus to replicate which is anticipated to cure the HDV infection.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.

 

• JNJ-73763989: Janssen Pharmaceuticals

Janssen “breakthrough” drug JNJ-73763989 is currently being evaluated for the treatment of chronic hepatitis delta virus infection. The drug is a liver-targeted antiviral class molecule designed to treat HVB and HVD infection via RNA interference mechanism. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.

 

For further information, refer to the detailed Chronic Hepatitis Delta Virus Infection Drugs Launch, Chronic Hepatitis Delta Virus Infection Developmental Activities, and Chronic Hepatitis Delta Virus Infection News, click here for Chronic Hepatitis Delta Virus Infection Ongoing Clinical Trial Analysis

 

Chronic Hepatitis Delta Virus Infection Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Chronic Hepatitis Delta Virus (HDV) Infection. The companies which have their Chronic Hepatitis Delta Virus (HDV) Infection drug candidates in the mid to advanced stage, i.e. phase III and Phase III include, Eiger Biopharmaceuticals and others.

 

Chronic Hepatitis Delta Virus Infection Segmentation: Phases

 

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Chronic Hepatitis Delta Virus (HDV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Find out more about the Chronic Hepatitis Delta Virus Infection Pipeline Segmentation, Therapeutics Assessment, and Chronic Hepatitis Delta Virus Infection Emerging Drugs @ Chronic Hepatitis Delta Virus Infection Treatment Landscape

 

Scope of the Chronic Hepatitis Delta Virus Infection Pipeline Report

• Coverage- Global

 

• Chronic Hepatitis Delta Virus Infection Companies- Janssen Pharmaceuticals, Eiger Biopharmaceutical, Pharma Essentia, Vir Biotechnology, Inc., Eiger BioPharmaceutical, Hoffmann-La Roche, Merck Sharp & Dohme LLC, and others

 

• Chronic Hepatitis Delta Virus Infection Pipeline Therapies- Pegylated Interferon (PEG-IFN) alfa-2a, tenofovir, and others

 

• Chronic Hepatitis Delta Virus Infection Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Chronic Hepatitis Delta Virus Infection Pipeline Companies and Therapies, click here @ Chronic Hepatitis Delta Virus Infection Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Hepatitis Delta Virus (HDV) Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Hepatitis Delta Virus (HDV) Infection – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Chronic Hepatitis Delta Virus (HDV) Infection Collaboration Deals
9. Late Stage Products (Phase III)
10. Lonafarnib: Eiger Biopharmaceuticals
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. JNJ-73763989: Janssen Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. Chronic Hepatitis Delta Virus (HDV) Infection Key Companies
19. Chronic Hepatitis Delta Virus (HDV) Infection Key Products
20. Chronic Hepatitis Delta Virus (HDV) Infection- Unmet Needs
21. Chronic Hepatitis Delta Virus (HDV) Infection- Market Drivers and Barriers
22. Chronic Hepatitis Delta Virus (HDV) Infection- Future Perspectives and Conclusion
23. Chronic Hepatitis Delta Virus (HDV) Infection Analyst Views
24. Chronic Hepatitis Delta Virus (HDV) Infection Key Companies
25. Appendix

 

Got Queries? Find out the related information on Chronic Hepatitis Delta Virus Infection Mergers and acquisitions, Chronic Hepatitis Delta Virus Infection Licensing Activities @ Chronic Hepatitis Delta Virus Infection Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/